Inclusion Criteria:

- Patients with measurable, histological diagnosis of HCC and whose disease is not
amenable to surgical or regional therapy.

- Prior allowed therapy: surgery, regional therapy (if more than 6 weeks have elapsed
from therapy and if there is an indicator lesion outside the treated area or if there
is clear evidence of progression in the treated lesion), or adjuvant sorafenib (if
disease relapsed more than 6 months after completion of adjuvant therapy).

- Patient with cirrhosis must have Childs-Pugh score of either A or B7 (See Appendix B)

- Performance status of 0-2. (See Appendix C)

- Organ function requirements: hemoglobin > 9.0mg/dl; granulocyte count > 1,000 /mm3 ,
platelets > 40,000/mm3 , ALT/AST up to 5 times the institutional upper limit of
normal, Alkaline Phosphatase < 4 times the institutional upper limit of normal and
serum creatinine < 2mg/dl.

- Patients must provide verbal and written informed consent to participate in the
study.

- Patients - both males and females - with reproductive potential (ie, menopausal for
less than 1 year and not surgically sterilized) must practice effective contraceptive
measures throughout the study. Women of childbearing potential must provide a
negative pregnancy test (serum or urine) within 14 days prior to registration.

Exclusion Criteria:

- Patients with mixed histology or fibrolamellar variant.

- Fasting glucose >150 mg/dl and any prior history of diabetes

- Patients with Type 1 diabetes mellitus or Type 2 diabetes mellitus currently
requiring insulinotropic or insulin therapy

- Prior systemic therapy for metastatic disease.

- QTc interval > 450 msec at baseline;

- Concomitant drugs that prolong the QTc interval;

- Significant cardiac disease defined as: congestive heart failure (NYHA class 2 or
higher- See Appendix D) or active coronary artery disease (MI within 6 months of
study enrollment)

- Pregnant or breast-feeding females

- Serious active infections

- Encephalopathy

- Uncontrolled ascites defined as symptomatic ascites not controlled with diuretic
treatments.

- Active second primary malignancy except for is situ carcinoma of the cervix or
adequately treated basal cell carcinoma of the skin within less than one year of
enrollment into the study.

- Use of drugs that have a known risk of causing Torsades de Pointes (TdP) ('Torsades
List' on www.azcert.org/medical-pros/drug-lists/bycategory.cfm, see Appendix E) are
prohibited within 14 days prior to enrollment.

- Use of the potent CYP1A2 inhibitors such as ciprofloxacin and fluvoxamine. Other less
potent CYP1A2 inhibitors/inducers are not excluded.

- Patients with a history of poorly controlled gastrointestinal disorders that could
affect the absorption of study drug (e.g., Crohn's disease, ulcerative colitis, etc)